Short Interest Coverage: Is Aveo Pharmaceuticals Incorporated (NASDAQ:AVEO)’s Fuel Running Low? Reports Show More Sellers

November 25, 2016 - By Hazel Jackson   ·   0 Comments

Short Interest Coverage: Is Aveo Pharmaceuticals Incorporated (NASDAQ:AVEO)’s Fuel Running Low? Reports Show More Sellers

The stock of Aveo Pharmaceuticals Incorporated (NASDAQ:AVEO) registered an increase of 2.22% in short interest. AVEO’s total short interest was 1.09M shares in November as published by FINRA. Its up 2.22% from 1.07 million shares, reported previously. With 234,400 shares average volume, it will take short sellers 5 days to cover their AVEO’s short positions. The short interest to Aveo Pharmaceuticals Incorporated’s float is 1.74%. The stock increased 0.27% or $0.002 on November 23, hitting $0.635. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has declined 36.00% since April 22, 2016 and is downtrending. It has underperformed by 41.41% the S&P500.

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $48.30 million. The Company’s platform delivers insights into cancer and related disease. It currently has negative earnings. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380.

Insitutional Activity: The institutional sentiment decreased to 0.44 in 2016 Q2. Its down 2.19, from 2.63 in 2016Q1. The ratio fall, as 5 funds sold all AVEO Pharmaceuticals, Inc. shares owned while 3 reduced positions. 10 funds bought stakes while 11 increased positions. They now own 29.13 million shares or 110.53% more from 13.83 million shares in 2016Q1.
Moreover, Vanguard has 0% invested in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) for 2.47 million shares. Springbok Capital Mngmt Ltd holds 0% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) for 1,600 shares. Moreover, First Manhattan Com has 0% invested in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) for 1,000 shares. Geode Mngmt Ltd Com last reported 303,283 shares in the company. Schwab Charles Management Inc last reported 15,100 shares in the company. Deutsche Bancorp Ag accumulated 0% or 44 shares. Susquehanna Group Llp has 0% invested in the company for 95,403 shares. Wells Fargo & Mn has invested 0% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Manufacturers Life Insur The owns 1,190 shares or 0% of their US portfolio. Blackrock holds 669 shares or 0% of its portfolio. State Street owns 25,375 shares or 0% of their US portfolio. Guggenheim holds 0% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) for 18,592 shares. The Texas-based Bridgeway Cap Mngmt has invested 0.01% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Morgan Stanley last reported 0% of its portfolio in the stock. Retail Bank Of America Corporation De, a North Carolina-based fund reported 5,503 shares.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Ratings Coverage

Out of 2 analysts covering AVEO Pharmaceuticals (NASDAQ:AVEO), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. AVEO Pharmaceuticals has been the topic of 2 analyst reports since March 30, 2016 according to StockzIntelligence Inc. The company was initiated on Thursday, May 19 by Piper Jaffray. FBR Capital initiated AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) on Wednesday, March 30 with “Outperform” rating.

AVEO Company Profile

AVEO Pharmaceuticals, Inc. (AVEO), incorporated on October 19, 2001, is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI). Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 inhibits the activity of the ErbB3 receptor. AV-380 is a humanized IgG1 inhibitory monoclonal antibody.

More recent AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) news were published by: Marketwatch.com which released: “AVEO Pharmaceuticals Inc.” on October 08, 2010. Also Bostonglobe.com published the news titled: “Aveo reeling after FDA’s rejection of kidney cancer drug” on August 26, 2013. Thestreet.com‘s news article titled: “AVEO Pharmaceuticals (AVEO) Stock Higher Today After Analyst Upgrade” with publication date: March 09, 2015 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Hazel Jackson


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>